检索结果-南通市图书馆

Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2024年第5期16卷 809-821页

作者： yuan-Yao Zhang Sen Luo Hai li Shu-Ning Sun Xian-Bo Wang Xin Zheng Yan Huang Bei-ling li Yan-Hang Gao Zhi-Ping Qian feng liu Xiao-Bo Lu jun-Ping liu Hao-Tang Ren Yu-Bao Zheng Hua-Dong Yan Guo-Hong Deng liang Qiao Yan Zhang wen-Yi Gu Xiao-Mei Xiang Yi Zhou Yi-Xin Hou Qun Zhang Yan Xiong Cong-Cong Zou jun Chen Ze-Bing Huang Xiu-Hua Jiang Ting-Ting Qi yuan-yuan Chen Na Gao Chun-Yan liu Wei yuan Xue Mei Jing li Tao li Rong-Jiong Zheng Xin-Yi Zhou jun Zhao Zhong-Ji Meng department of Infectious Disease Institute of Biomedical ResearchRegulatory Mechanism and Targeted Therapy for Liver Cancer Shiyan Key LaboratoryHubei provincial Clinical Research Center for Precise Diagnosis and Treatment of Liver CancerTaihe HospitalHubei University of MedicineShiyan 442000Hubei ProvinceChina department of Gastroenterology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China department of Infectious Diseases Southwest HospitalThe Third Military Medical University(Army Medical University)Chongqing 400000China Center of Integrative Medicine Beijing Ditan HospitalCapital Medical UniversityBeijing 100020China department of Infectious Diseases Institute of Infection and ImmunologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430020Hubei ProvinceChina department of Infectious Diseases Hunan Key Laboratory of Viral HepatitisXiangya HospitalCentral South UniversityChangsha 110051Hunan ProvinceChina Hepatology Unit Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina department of Hepatology The First Hospital of Jilin UniversityChangchun 130021Jilin ProvinceChina department of liver Intensive Care Unit Shanghai Public Health Clinical CentreFudan UniversityShanghai 200093China Tianjin Institute of Hepatology Nankai University Second People's HospitalTianjin 300192China Infectious Disease Center The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830054Xinjiang Uygur Autonomous RegionChina department of Infectious Diseases and Hepatology The Second Hospital of Shandong UniversityJinan 250000Shandong ProvinceChina State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious DiseaseThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310000Zhejiang ProvinceChina department of Infectious Diseases The Thir

BACKGROUND Acute-on-chronic liver disease(AoCLD)accounts for the majority of patients hospitalized in the department of Hepatology or Infectious *** To explore the characterization of AoCLD to provide theoretical guidance for the accurate diagnosis and prognosis of *** Patients with AoCLD from the Chinese Acute-on-Chronic liver Failure(ACLF)study cohort were included in this *** clinical characteristics and outcomes,and the 90-d survival rate associated with each clinical type of AoCLD were analyzed,using the Kaplan-Meier method and the log-rank *** A total of 3375 patients with AoCLD were enrolled,including 1679(49.7%)patients with liver cirrhosis acute decompensation(LC-AD),850(25.2%)patients with ACLF,577(17.1%)patients with chronic hepatitis acute exacer-bation(CHAE),and 269(8.0%)patients with liver cirrhosis active phase(LC-A).The most common cause of chronic liver disease(CLD)was HBV infection(71.4%).The most common precipitants of AoCLD was bacterial infection(22.8%).The 90-d mortality rates of each clinical subtype of AoCLD were 43.4%(232/535)for type-C ACLF,36.0%(36/100)for type-B ACLF,27.0%(58/215)for type-A ACLF,9.0%(151/1679)for LC-AD,3.0%(8/269)for LC-A,and 1.2%(7/577)for *** HBV infection is the main cause of CLD,and bacterial infection is the main precipitant of *** most common clinical type of AoCLD is *** diagnosis and timely intervention are needed to reduce the mortality of patients with LC-AD or ACLF.

关键词： Acute-on-chronic liver disease Acute-on-chronic liver failure liver cirrhosis Clinical features Prognosis

Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2015年第5期13卷 341-346页

作者： Chen ling yuan Wang Ying-lu feng Ya-ni Zhang jun li Xin-rui Hu li-na Wang Mao-feng Zhong Xiao-feng Zhai Irene Zolotukhin Arun Srivastava Chang-quan ling Division of Cellular and Molecular Therapy Department of Pediatrics University of Florida College of Medicine Shands Cancer Center University of Florida College of Medicine Changhai Hospital of Traditional Chinese Medicine Second Military Medical University department of Traditional Chinese Medicine 401 Hospital of the Chinese People’s Liberation Army shanghai university of Traditional Chinese Medicine E-Institute of TCM Internal Medicine Shanghai Municipal Education Commission

Recombinant adeno-associated virus （rAAV） serotype 2, 3 and 8 vectors are the most promising liver- tropic AAV serotype vectors. liver diseases are significant problems in china. However, to date, few studies on AAV neutralizing antibodies （Nabs） were working with the Chinese population or with the rAAV3 vectors. The present study aimed to determine the prevalence of Nabs in Chinese population against wild-type AAV2, AAV3 and AAV8 capsids as well as additional two AAV3 variants. In addition, we performed a preliminary analysis to investigate the potential influence of traditional Chinese medicine body constitutions on AAV Nabs. Our work demonstrated that the majority of healthy Chinese subjects were positive for AAV Nabs, with the order of AAV2 〉 AAV3 = AAVLK03 〉 AAV8. There was no difference between： 1）AAV3 and its variants; 2） male and female subjects; and 3） different age cohorts （〈 35, 36- 50, and 〉 51 years old）. People in the Qi-deficiency constitution had significantly increased AAV8 Nabs than people in the Gentleness constitution. Our studies may have impact on the future clinical design of AAV-based gene therapy in the Chinese population.

关键词： medicine, Chinese traditional recombinant adeno-associated virus vector neutralizing antibodies body constitutions

Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma

在线全文

学校读者我要写书评

暂无评论

Journal of Zhejiang university-Science B(Biomedicine & Biotechnology) 2011年第10期12卷 787-795页

作者： jun HU li-rong ZHU Zhi-qing liANG yuan-guang MENG Hong-yan GUO Peng-peng QU Cai-ling MA Cong-jian XU Bi-bo yuan department of Gynecology Peking University First Hospital Beijing 100034 China department of Gynecology Southwest Hospital of Third Military Medical University Chongqing 400038 China department of Gynecology Chinese PLA General Hospital ＆ Chinese PLA Postgraduate Medical School Beijing 100853 China department of Gynecology Peking University Third Hospital Beijing 100191 China Tianjin Central Obstetrics and Gynecological Hospital Tianjin 300052 China department of Gynecology Xinjiang Medical University First Teaching Hospital Urumqi 830054 China shanghai Red House Hospital of Obstetrics and Gynecology Shanghai 200011 China department of Gynecology Tianjin Medical University General Hospital Tianjin 300052 China

Objective:To assess the clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma (EOC).Methods:A retrospective study of young EOC inpatients (≤40 years old) was performed during January 1994 and December 2010 in eight ***:Data were analyzed from 94 patients treated with fertility-sparing surgery with a median follow-up time of 58.7 *** histologic grade increased,overall survival (OS) and disease-free survival (DFS) of patients receiving fertility-sparing surgery *** staging surgery nor laparoscopy of early stage EOC with conservative surgery had a significant effect on OS or *** menstruation recommenced after chemotherapy in 89% of the fertility-sparing *** pregnancies among twelve patients were achieved by the end of the ***:Fertility-sparing treatment for patients with EOC Stage I Grade 1 could be cautiously considered for young *** surgical procedure and surgical route might not significantly influence the *** chemotherapy is not likely to have an evident impact on ovarian function or fertility in young patients.

关键词： Epithelial ovarian carcinoma Fertility-sparing treatment Overall survival Disease-free survival Pregnancy

Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in china

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第31期28卷 4417-4430页

作者： Zi-Xuan Shen Dan-Dan Wu Jie Xia Xian-Bo Wang Xin Zheng Yan Huang Bei-ling li Zhong-Ji Meng Yan-Hang Gao Zhi-Ping Qian feng liu Xiao-Bo Lu Jia Shang Hua-Dong Yan Yu-Bao Zheng wen-Yi Gu Yan Zhang Jian-Yi Wei wen-Ting Tan Yi-Xin Hou Qun Zhang Yan Xiong Cong-Cong Zou jun Chen Ze-Bing Huang Xiu-Hua Jiang Sen Luo yuan-yuan Chen Na Gao Chun-Yan liu Wei yuan Xue Mei Jing li Tao li Xin-Yi Zhou Guo-Hong Deng Jin-jun Chen Xiong Ma Hai li department of Gastroenterology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China shanghai Institute of Digestive Disease Key Laboratory of Gastroenterology and HepatologyChinese Ministry of HealthShanghai Jiao Tong UniversityShanghai 200001China department of Infectious Diseases Southwest HospitalThe Third Military Medical University(Army Medical University)Chongqing 400038China Center of Integrative Medicine Beijing Ditan HospitalCapital Medical UniversityBeijing 100102China department of Infectious Diseases Institute of Infection and ImmunologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina department of Infectious Diseases Hunan Key Laboratory of Viral HepatitisXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Hepatology Unit Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina department of Infectious Disease Taihe HospitalHubei University of MedicineShiyan 430418Hubei ProvinceChina department of Hepatology The First Hospital of Jilin UniversityChangchun 130031Jilin ProvinceChina department of liver Intensive Care Unit Shanghai Public Health Clinical CentreFudan UniversityShanghai 201508China Tianjin Institute of Hepatology Nankai University Second People’s HospitalTianjin 300102China department of Infectious Diseases and Hepatology The Second Hospital of Shandong UniversityJinan 250033Shandong ProvinceChina Infectious Disease Center The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830054XinjiangChina department of Infectious Diseases Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina department of Infectious Diseases Hwamei HospitalThe Second Hospital of NingboUniversity of Chinese Academy of SciencesNingbo 315153Zhejiang ProvinceChina department of Infectious Diseases The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 5

BACKGROUND Autoimmune liver disease(AILD)has been considered a relatively uncommon disease in china,epidemiological data for AILD in patients with cirrhosis and acute decompensation(AD)is *** To investigate the prevalence,outcome and risk factors for AILD in cirrhotic patients complicated with AD in *** We collected data from patients with cirrhosis and AD from two prospective,multicenter cohorts in hepatitis B virus endemic *** were regularly followed up at the end of 28-d,90-d and 365-d,or until death or liver transplantation(LT).The primary outcome in this study was 90-d LTfree ***-on-chronic liver failure(ACLF)was assessed on admission and during 28-d hospitalization,according to the diagnostic criteria of the European Association for the Study of the liver(EASL).Risk factors for death were analyzed with logistic regression *** In patients with cirrhosis and AD,the overall prevalence of AILD was 9.3%(242/2597).Prevalence of ACLF was significantly lower in AILD cases(14%)than those with all etiology groups with cirrhosis and AD(22.8%)(Pliary cirrhosis(PBC),autoimmune hepatitis(AIH)and PBC-AIH overlap syndrome(PBC/AIH)were 50.8%,28.5%and 12.0%,*** ACLF patients,the proportions of PBC,AIH and PBC/AIH were 41.2%,29.4% and 20.6%.28-d and 90-d mortality were 43.8% and 80.0% in AILD-related *** etiology of AILD had no significant impact on 28-d,90-d or 365-d LTfree mortality in patients with cirrhosis and AD in both univariate and multivariate *** bilirubin(TB),hepatic encephalopathy(HE)and blood urea nitrogen(BUN)were independent risk factors for 90-d LT-free mortality in multivariate *** development of ACLF during hospitalization only independently correlated to TB and international normalized *** AILD was not rare in hospitalized patients with cirrhosis and AD in china,among which PBC was the m

关键词： Prevalence Autoimmune liver disease Cirrhosis and acute decompensation Mortality Acuteon-chronic liver failure

CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta,alpha,beta,and gamma

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3142-3154页

作者： Jiejie Geng liang Chen Yufeng yuan Ke Wang Youchun Wang Chuan Qin Guizhen Wu Ruo Chen Zheng Zhang ding Wei Peng Du jun Zhang Peng lin Kui Zhang Yongqiang Deng Ke Xu Jiangning liu Xiuxuan Sun Ting Guo Xu Yang Jiao Wu Jianli Jiang ling li Kun Zhang Zhe Wang Jing Zhang Qingguo Yan Hua Zhu Zhaohui Zheng Jinlin Miao Xianghui Fu fengfan Yang Xiaochun Chen Hao Tang Yang Zhang Ying Shi Yumeng Zhu Zhuo Pei Fei Huo Xue liang Yatao Wang Qingyi Wang wen Xie Yirong li Mingyan Shi Huijie Bian Ping Zhu Zhi-Nan Chen National Translational Science Center for Molecular Medicine&department of Cell Biology Fourth Military Medical UniversityXi'an 710032China School of Medicine Shanghai UniversityShanghai 200444China Zhongnan Hospital of Wuhan university Wuhan 430071China Division of HIV/AIDS and Sex-transmitted Virus Vaccines Institute for Biological Product ControlNational Institutes for Food and Drug Control(NIFDC)and WHO Collaborating Center for Standardization and Evaluation of BiologicalsBeijing 102629China Institute of Laboratory Animals Science Chinese Academy of Medical SciencesBeijing 100071China NHC Key Laboratory of Biosafety National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and PreventionBeijing 100871China Beijing Institute of Biotechnology Beijing 100871China department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi'an 710032China Beijing Institute of Microbiology and Epidemiology Beijing 100071China School of Basic Medicine Fourth Military Medical UniversityXi'an 710032China Jiangsu Pacific Meinuoke Biopharmceutical Co.Ltd Changzhou 213022China

SARS-CoV-2 mutations contribute to increased viral transmissibility and immune escape,compromising the effectiveness of existing vaccines and neutralizing *** in-depth investigation on COVID-19 pathogenesis is urgently needed to develop a strategy against SARS-CoV-2 ***,we identified CD147 as a universal receptor for SARS-CoV-2 and its ***,Meplazeumab,a humanized anti-CD147 antibody,could block cellular entry of SARS-CoV-2 and its variants-alpha,beta,gamma,and delta,with inhibition rates of 68.7,75.7,52.1,52.1,and 62.3%at 60μg/ml,***,humanized CD147 transgenic mice were susceptible to SARS-CoV-2 and its two variants,alpha and *** infected,these mice developed exudative alveolar pneumonia,featured by immune responses involving alveoli-infiltrated macrophages,neutrophils,and lymphocytes and activation of IL-17 signaling ***,we proposed that severe COVID-19-related cytokine storm is induced by a"spike protein-CD147-CyPA signaling axis":Infection of SARS-CoV-2 through CD147 initiated the JAK-STAT pathway,which further induced expression of cyclophilin A(CyPA);CyPA reciprocally bound to CD147 and triggered MAPK ***,the MAPK pathway regulated the expression of cytokines and chemokines,which promoted the development of cytokine ***,Meplazumab could effectively inhibit viral entry and inflammation caused by SARS-CoV-2 and its ***,our findings provided a new perspective for severe COVID-19-related ***,the validated universal receptor for SARS-CoV-2 and its variants can be targeted for COVID-19 treatment.

关键词： CD147 cytokine storm

Consensus on the Diagnosis and Treatment of Melasma in china （2021 Version）#

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Dermatology And Venereology 2021年第3期04卷 133-139页

作者： Pigmentary Disorder Group Combination of Traditional and Western Medicine Dermatology Research Center for Vitiligo Chinese Society of Dermatology Working Group on Pigmentary Disorders china Dermatologist Association Gao Tian-wen Gu Hua He li Lei Tie-Chi li Ming li Tie-Nan li Chun-Ying lin Tong Mu Kuan-Hou Tu Cai-Xia wen Hai Wu Ji-yuan Xu Ai-E Zhang jun-ling Zhen Zhi-Zhong department of Dermatology Xijing Hospital The Fourth military medical university Xi’an Shanxi 710032 chinadepartment of Dermatology The First Affiliated Hospital of Kunming medical university Kunming Yunnan 650032 chinaRenmin Hospital of Wuhan university Wuhan Hubei 430000 Zhongshan Hospital of Fudan university shanghai 200000 The 7th Municipal People’s Hospital in Shenyang Shenyang liaoning 110000 chinaHospital for Skin Diseases (Institute of Dermatology) Chinese Academy of medical Sciences and Peking Union medical College Nanjing Jiangsu 210000 The First Affiliated Hospital of Xi’an Jiaotong university The second Affiliated Hospital of Dalian medical university Dalian 116000 Changzheng Hospital of Navy medical university The First Hospital of Wuhan City The Third People’s Hospital of Hangzhou Hangzhou Zhejiang 310000 chinaThe Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine Tianjing 300000 Huashan Hospital of Fudan university shanghai 20000 Chin

The pathogenesis of melasma is believed to be related to heredity, sun exposure, sex hormones, and other factors. The mechanisms underlying the development of melasma include increased melanin synthesis, vascular proliferation within the skin lesions, inflammation, and skin barrier dysfunction. The diagnosis of melasma is mainly based on clinical manifestations and noninvasive techniques. Coupling with recent research progress in melasma, the present consensus comprehensively elaborates the etiology, pathogenesis, clinical manifestations, staging, classification, diagnosis, and treatment of melasma to improve the diagnostic and therapeutic skills of Chinese dermatologists.

关键词： diagnosis expert consensus melasma therapy

Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese medical Journal 2019年第15期132卷 1765-1772页

作者： Yao Chen Wei-jun Fu Lan-Ping Xu Han-Yun Ren Yong-Rong Lai Dai-Hong liu lin liu Zi-Min Sun yuan-Bin Wu Xin Wang ling-Hui Xia Ming Jiang Tong-lin Hu ding-Ming Wan Xiao-jun Huang department of Hematology Peking University People's Hospital Peking University Institute of Hematology Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044 China department of Hematology Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 China Hematologic Disease Center First Affiliated Hospital of Xinjiang Medical UniversityXinjiang Uygur Autonomous Region Research Institute of Hematology Urumqi Xinjiang 830054 China department of Hematology Zhejiang Provincial Hospital of Traditional Chinese Medicine Zhejiang International Exchange Center of Clinical Traditional Chinese Medicine The First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang 310006 China department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China Peking-Tsinghua Center for life Sciences Beijing 100871 China department of Hematology The Myeloma & Lymphoma Center Changzheng Hospital The Second Military Medical University Shanghai 200003 China department of Hematology Peking University First Hospital Beijing 100034 China department of Hematology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530021 China department of Hematology Chinese People's Liberation Army General Hospital Beijing 100853 China department of Hematology The First Affiliated Hospital of Chongqing Medical University Chongqing 400042 China department of Hematology Anhui Provincial Hospital The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui 230001 China department of Hematology Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong 510530 China department of Hematology Shandong Provincial Hospital Jinan Shandong 250021 China

Background:Allogeneic stem-cell transplantation (SCT) is a well-established immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graft-vs.-myeloma *** multicenter investigation aimed to analyze the complications and survival of haploidentical SCT in patients with MM,and compare the main outcomes with matched-related donors (MRDs).Methods:Haploidentical and MRD SCT was identified from a cohort of 97 patients with MM who received a myeloablative transplantation in 13 hospitals from May 2001 to December 2017.A matched-pair analysis was *** each haplo recipient,the recipients were randomly selected from the MRD group and were matched according to the following criteria:year of the hematopoietic SCT (±2 years),disease status at transplantation,and the length of ***:Seventy cases received MRD and 27 received haploidendcal *** two groups showed no significant ifferences regarding age,gender,cytogenetic risk,and diagnostic *** cumulative incidences of non-relapse mortality (NRM) at1 and 3 years based on donor type were 20.5%(95% confidence interval [CI],10.90-30.10%) and 24.2%(95% CI,13.81-34.59%) for the MRD group and 16.80%(95% CI,1.71-31.89%) and 28.70%(95% CI,8.71-48.69%) for the haplo group,*** incidence of NRM did not differ significantly between the two groups (x2 =0.031,P =0.861).The cumulative incidences of progression-free survival (PFS) and 1 year and 3 years by type of donors were 59.8 %(95 % CI,48.24-71.36 %) and 45.4 %(95 % CI,33.44-57.36%),and 65.6%(95% CI,47.18-84.02%) and 26.8%(95% CI,7.59-46.01%) for MRD and haploidentical donor,*** incidence of PFS did not differ significantly between the two groups (x2 =0.182,P =0.670).In multivariate analyses,no statistically significant differences were observed between haploidentical and MRD for relapse,NRM,PFS,and overall *** were no statistically differences on main outcomes after ha

关键词： Allogeneic stem-cell transplantation Multiple myeloma

烫伤对大鼠下丘脑视上核内皮素-1基因转录和蛋白含量的影响

在线全文

学校读者我要写书评

暂无评论

生理学报 2000年第5期52卷 385-389页

作者：蒋应明袁文俊向正华缪为民林丽李玲焦炳华第二军医大学生理学教研室 department of Hygieology and Toxicology Second Military Medical UniversityShanghai 200433

用原位杂交和免疫组织化学方法观察了烫伤后下丘脑视上核 (SON)内皮素 1(ET 1)基因转录和蛋白含量的变化 ,并用通用图像颗粒分析法估计ET 1mRNA阳性杂交信号的强度和ET 1样免疫反应物 (ET 1 ir)的免疫反应强度。与对照组相比 ,烫伤后 15... 详细信息

用原位杂交和免疫组织化学方法观察了烫伤后下丘脑视上核 (SON)内皮素 1(ET 1)基因转录和蛋白含量的变化 ,并用通用图像颗粒分析法估计ET 1mRNA阳性杂交信号的强度和ET 1样免疫反应物 (ET 1 ir)的免疫反应强度。与对照组相比 ,烫伤后 15min ,SON神经元胞浆内ET 1mRNA阳性杂交信号未见明显变化 ;而在烫伤后 6 0和 180min ,ET 1mRNA阳性杂交信号强度分别较比照组增加 35 1% (P <0 0 5 )和 6 2 4% (P <0 0 1)。在烫伤后 15min ,SON神经元胞浆内ET 1 ir明显减少 ,仅为对照组的 8 5 % ,显著低于对照组 (P <0 0 1)。烫伤后 6 0和180min免疫反应物强度较烫伤后 15min有所回升 ,分别为对照组的 31 5 %和 5 2 4% ,但仍显著低于对照组 (P <0 0 1)。用Northern法检测烫伤后下丘脑ET 1mRNA含量和长度变化。结果显示 ,在烫伤后 15min ,ET 1mRNA含量变化不显著 ,在烫伤后 6 0min显著增多 (P <0 0 5 ) ,在烫伤后 180min继续增至对照组 2 5倍 ,但ET 1mRNA长度在烫伤前后并无改变。以上结果表明 ,烫伤后大鼠下丘脑SONET 1mRNA含量增加 ,而ET 1 ir含量在烫伤后180min内维持在低水平。鉴于SON具有神经内分泌作用 ,烫伤后SON内ET 1mRNA和ET 1 ir的变化提示 ,ET 1在烫伤后的病理生理变化中可能有重要的神经内分泌作?

关键词：内皮素-1 mRNA 内皮素-1 烫伤下丘脑视上核

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1:interim analysis of the randomized,controlled,phase 3,non-inferiority TALENT study

在线全文

学校读者我要写书评

暂无评论

Chinese medical Journal 2020年第24期133卷 2919-2927页

作者： Bin Su Cheng Yao Qing-Xia Zhao Wei-Ping Cai Min Wang Hong-Zhou Lu yuan-yuan Chen li liu Hui Wang Yun He Yu-Huang Zheng ling-Hua li Jin-feng Chen Jian-Hua Yu Biao Zhu Min Zhao Yong-Tao Sun wen-Hui Lun Wei Xia li-jun Sun li-li Dai Tai-Yi Jiang Mei-Xia Wang Qing-Shan Zheng Hai-Yan Peng Yao Wang Rong-Jian Lu Jian-Hua Hu Hui Xing Yi-Ming Shao Dong Xie Tong Zhang Fu-Jie Zhang Hao Wu TALENT Study Team Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijing 100069China Frontier Biotechnologies Inc. NanjingJiangsu 211122China department of Infectious Diseases Infectious Disease Hospital of Henan ProvinceZhengzhouHenan 450061China Infectious Disease Center Guangzhou Eighth People’s HospitalGuangzhou Medical UniversityGuangzhouGuangdong 510060China Institute of HIV/AIDS The First Hospital of ChangshaChangshaHunan 410005China department of Infectious Diseases Shanghai Public Health Clinical CenterFudan UniversityShanghai 201508China department of Infectious Diseases National Clinical Center for Infectious DiseasesShenzhen Third People’s HospitalShenzhenGuangdong 518112China department of Infectious Diseases The Second Xiangya HospitalCentral South UniversityChangshaHunan 410011China department of Infectious Diseases Xixi Hospital of HangzhouHangzhouZhejiang 310023China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious DiseasesThe First Affiliated HospitalZhejiang UniversityHangzhouZhejiang 310003China National Clinical Research Center for Infectious Diseases the Fifth Medical Center of PLA General HospitalBeijing 100039China department of Infectious Diseases Tangdu HospitalThe Fourth Military Medical UniversityXi’anShaanxi 710038China Clinical and Research Center of Infectious Diseases Beijing Ditan HospitalCapital Medical UniversityBeijing 100015China Center for Drug Clinical Research Shanghai University of Traditional Chinese MedicineShanghai 201203China Beijing Co-CRO medical Development Co. Ltd.Beijing 100711China State Key Laboratory for Infectious Disease Prevention and Control National Center for AIDS/STD Control and PreventionChinese Center for Disease Control and PreventionBeijing 102206China 不详

Background:Albuvirtide is a once-weekly injectable human immunodeficiency virus(HIV)-1 fusion *** present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral ***:We carried out a 48-week,randomized,controlled,open-label non-inferiority trial at 12 sites in *** on the World Health Organization(WHO)-recommended first-line treatment for>6 months with a plasma viral load>1000 copies/mL were enrolled and randomly assigned(1:1)to receive albuvirtide(once weekly)plus ritonavir-boosted lopinavir(ABT group)or the WHO-recommended second-line treatment(NRTI group).The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 ***-inferiority was prespecified with a margin of 12%.Results:At the time of analysis,week 24 data were available for 83 and 92 patients,and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups,*** 48 weeks,80.4%of patients in the ABT group and 66.0%of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL,meeting the criteria for *** the per-protocol population,the superiority of albuvirtide over NRTI was *** frequency of grade 3 to 4 adverse events was similar in the two groups;the most common adverse events were diarrhea,upper respiratory tract infections,and grade 3 to 4 increases in triglyceride *** function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT ***:The TALENT study is the first phase 3 trial of an injectable long-acting HIV *** interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatme

关键词： HIV Fusion inhibitor Albuvirtide LPV/r Phase 3 clinical trial